Investigators evaluated ctDNA as a prognostic marker for patients with follicular lymphoma in the phase III GALLIUM trial.

While most patients with follicular lymphoma (FL) who relapse within 24 months after first-line treatment (POD24) have a poor prognosis, some show notable survival. POD24 FL patients constituted 15% ...

—Recent studies suggest progress toward the development of more-refined prognostic tools for identifying patients with follicular lymphoma at high risk of early relapse. Reviewed by Chaitra Ujjani, MD ...

Prognostic value of the absolute lymphocyte count reduction in patients with diffuse large B-cell lymphoma treated with R-CHOP. Background: Tracer retention on post-therapy 18F-fluorodeoxglucose (FDG) ...

Rituximab plus CVP chemotherapy vs. CVP alone as first-line treatment for follicular lymphoma: Treatment effect according to baseline prognostic factors This is an ASCO Meeting Abstract from the 2005 ...